Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MXCT MaxCyte Inc
- Stocks
- Healthcare
- NASDAQ: MXCT
Price (delayed)
$2.39
Market cap
$254.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.4
Enterprise value
$249.54M
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to
Highlights
MXCT's quick ratio is up by 12% since the previous quarter but it is down by 7% year-on-year
The company's gross profit fell by 22% YoY and by 3.3% QoQ
The EPS has contracted by 14% YoY and by 2.6% from the previous quarter
Key stats
What are the main financial stats of MXCT
Market
Valuations
Earnings
Shares outstanding
106.32M
Market cap
$254.1M
Enterprise value
$249.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.27
Price to sales (P/S)
6.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.62
Revenue
$37.68M
Gross profit
$30.48M
Operating income
-$51.22M
Net income
-$41.79M
EBIT
-$41.79M
EBITDA
-$36.95M
Free cash flow
-$32.96M
Per share
Balance sheet
Liquidity
EPS
-$0.4
EPS diluted
-$0.4
Free cash flow per share
-$0.31
Book value per share
$1.88
Revenue per share
$0.36
TBVPS
$2.13
Total assets
$229.96M
Total liabilities
$30.55M
Debt
$18.82M
Equity
$199.41M
Working capital
$143.02M
Debt to equity
0.09
Current ratio
12.23
Quick ratio
11.29
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
-98.1%
Gross margin
80.9%
Net margin
-110.9%
Operating margin
-135.9%
Return on assets
-17.2%
Return on equity
-19.9%
Return on invested capital
-19.6%
Return on capital employed
-19.2%
Return on sales
-110.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MXCT stock price
How has the MaxCyte stock price performed over time
Intraday
4.82%
1 week
5.29%
1 month
-15.25%
1 year
-46.41%
YTD
-42.55%
QTD
-12.45%
Financial performance
How have MaxCyte's revenue and profit performed over time
Revenue
$37.68M
Gross profit
$30.48M
Operating income
-$51.22M
Net income
-$41.79M
Gross margin
80.9%
Net margin
-110.9%
MXCT's net margin is down by 34% YoY and by 4.3% from the previous quarter
MXCT's operating margin is down by 26% YoY and by 2.6% QoQ
The company's gross profit fell by 22% YoY and by 3.3% QoQ
MXCT's net income is down by 14% YoY
Price vs fundamentals
How does MXCT's price correlate with its fundamentals
Growth
What is MaxCyte's growth rate over time
Valuation
What is MaxCyte stock price valuation
P/E
N/A
P/B
1.27
P/S
6.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.62
The EPS has contracted by 14% YoY and by 2.6% from the previous quarter
MXCT's P/B is 29% below its last 4 quarters average of 1.8
The equity has contracted by 12% YoY and by 3.3% from the previous quarter
MXCT's price to sales (P/S) is 27% less than its last 4 quarters average of 9.2
The revenue has declined by 14% year-on-year and by 2.5% since the previous quarter
Efficiency
How efficient is MaxCyte business performance
The ROS has contracted by 34% YoY and by 4.3% from the previous quarter
The return on equity has declined by 27% year-on-year and by 5% since the previous quarter
The ROA has contracted by 26% YoY and by 4.2% from the previous quarter
The ROIC has decreased by 21% YoY and by 6% from the previous quarter
Dividends
What is MXCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MXCT.
Financial health
How did MaxCyte financials performed over time
MXCT's quick ratio is up by 12% since the previous quarter but it is down by 7% year-on-year
The current ratio is up by 12% since the previous quarter but it has declined by 8% year-on-year
MXCT's debt is 91% less than its equity
MaxCyte's debt to equity has increased by 13% YoY
The equity has contracted by 12% YoY and by 3.3% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.